| Transcriptional regulation of cancer immune checkpoints: emerging strategies for immunotherapy S Venkatraman, J Meller, S Hongeng, R Tohtong, S Chutipongtanate Vaccines 8 (4), 735, 2020 | 21 | 2020 |
| Co-clinical trials: an innovative drug development platform for cholangiocarcinoma B Balasubramanian, S Venkatraman, KZ Myint, T Janvilisri, ... Pharmaceuticals 14 (1), 51, 2021 | 11 | 2021 |
| Effect of combining EGFR tyrosine kinase inhibitors and cytotoxic agents on cholangiocarcinoma cells B Boonsri, K Yacqub-Usman, P Thintharua, KZ Myint, T Sae-Lao, P Collier, ... Cancer Research and Treatment: Official Journal of Korean Cancer Association …, 2021 | 10 | 2021 |
| RTK25: A comprehensive molecular profiling strategy in cholangiocarcinoma using an integrated bioinformatics approach B Balasubramanian, S Venkatraman, T Janvilisri, T Suthiphongchai, ... Pharmaceuticals 14 (9), 898, 2021 | 7 | 2021 |
| Molecularly Guided Drug Repurposing for Cholangiocarcinoma: An Integrative Bioinformatic Approach S Venkatraman, B Balasubramanian, P Pongchaikul, R Tohtong, ... Genes 13 (2), 271, 2022 | 5 | 2022 |
| Upregulated LAMA3 modulates proliferation, adhesion, migration and epithelial‑to‑mesenchymal transition of cholangiocarcinoma cells K Islam, B Balasubramanian, S Venkatraman, P Thummarati, ... Scientific Reports 13 (1), 22598, 2023 | 1 | 2023 |
| Targeting FGFRs Using PD173074 as a Novel Therapeutic Strategy in Cholangiocarcinoma B Balasubramanian, K Yacqub-Usman, S Venkatraman, KZ Myint, ... Cancers 15 (9), 2528, 2023 | 1 | 2023 |
| Preclinical evidence for anaplastic lymphoma kinase inhibitors as novel therapeutic treatments for cholangiocarcinoma KZ Myint, M Sueca-Comes, P Collier, B Balasubramanian, ... Frontiers in Oncology 13, 2023 | 1 | 2023 |
| Bioinformatics and qPCR analyses of laminins’ cognate receptors in cholangiocarcinoma tissues reveal the integrin ITGB4 as a potential biomarker. K Islam, B Balasubramanian, S Venkatraman, J Puetkasichonpasutha, ... ScienceAsia 48 (4), 2022 | 1 | 2022 |
| In Silico Target Identification of Galangin, as an Herbal Flavonoid against Cholangiocarcinoma B Balasubramanian, S Venkatraman, KZ Myint, S Krobthong, ... Molecules 27 (14), 4664, 2022 | 1 | 2022 |
| FGF signalling as a therapeutic target in Cholangiocarcinoma B Balasubramanian, KZ Myint, K Yacqub-Usman, S Venkatraman, ... Cancer Science 112, 419-419, 2021 | 1 | 2021 |
| Targeting MYC at the intersection between cancer metabolism and oncoimmunology S Venkatraman, B Balasubramanian, C Thuwajit, J Meller, R Tohtong, ... Frontiers in Immunology 15, 1324045, 2024 | | 2024 |
| Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation KZ Myint, B Balasubramanian, S Venkatraman, S Phimsen, S Sripramote, ... Pharmaceuticals 17 (2), 197, 2024 | | 2024 |
| Exploring the potential of Galangin in Cholangiocarcinoma cells using a bioinformatics approach S Venkatraman, J Jantra, B Balasubramanian, KZ Myint, K Tawanttanakul, ... CANCER SCIENCE 112, 756-756, 2021 | | 2021 |
| ALK-independent Therapeutic Potential of Ceritinib in Cholangiocarcinoma KZ Myint, B Balasubramanian, S Venkatraman, J Jantra, K Chueajedton, ... CANCER SCIENCE 112, 536-536, 2021 | | 2021 |
| Sorafenib induces cytotoxicity in cholangiocarcinoma cell lines by inhibiting Akt signalling S Venkatraman, B Balasubramanian, KZ Myint, J Jantra, R Tohtong CANCER SCIENCE 109, 1383-1383, 2018 | | 2018 |
| Aberrant FGF/FGFR signaling as a mechanism of pathogenesis in Cholangiocarcinoma B Balasubramanian, KZ Myint, K Yacqub-Usman, S Venkatraman, ... CANCER SCIENCE 109, 999-999, 2018 | | 2018 |
Brinda BalasubramanianUniversity of NottinghamVerified email at nottingham.ac.uk
